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BACKGROUND: During perimenopause, vasomotor symptoms are known to have a detrimental effect 
on women’s functional ability and quality of life. For symptomatic women not eligible for hormonal 
therapy, desvenlafaxine is an option, but its safety margin and tolerability are not yet determined.  
METHODS: A computer-based literature search was done in the databases of MEDLINE, Cochrane 
library, and HINARI (Health InterNetwork Access to Research Initiative). Meta-analysis was conducted 
by including double-blind randomized controlled studies on the effectiveness and safety of 
desvenlafaxine in the treatment of hot flashes. The effectiveness, safety and tolerability of desvenlafaxine 
were determined by standardized mean differences (SMDs) and Mantel-Haenszel odds ratio. Subgroup 
analysis based on doses of desvenlafaxine and linear meta-regression analyses were performed for 
several covariates. Heterogeneity testing, the risk of bias assessment and sensitivity analyses were done.  
RESULTS: Desvenlafaxine was associated with a statistically significant reduction in the number and 
severity of daily moderate to severe hot flashes. The number of nighttime awakenings because of hot 
flashes was also significantly decreased. However, the rate of desvenlafaxine treatment discontinuation 
because of adverse events was a significantly higher than placebo treated women and the risk ratios of 
adverse events like asthenia, hypertension, anorexia, constipation, diarrhea, dry mouth, nausea, 
dizziness, insomnia, somnolence and mydriasis were very high.  
CONCLUSION: Desvenlafaxine is effective in the treatment of hot flashes but it is strongly associated 
with several adverse events and treatment discontinuation. Further clinical trials focusing only on 
desvenlafaxine related adverse events are highly warranted before it is approved for public use.   
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INTRODUCTION 
 
Although menopause (the last menses) is a 
physiological phenomenon that marks the end of a 
woman's reproductive age, the transition period 
before and after this signal is usually associated 
with vasomotor symptoms, vaginal symptoms, 
urinary incontinence, sexual dysfunction, and 
troubled sleeping (1). Up to 75% of the women in 
the perimenopausal age may experience 
vasomotor symptoms including hot flushes, 
sweating, palpitations and feelings of anxiety (2-
6). Vasomotor symptoms are known to have a 
detrimental effect on women’s functional ability 
and quality of life -poor sleep patterns, frequently 
disturbed mood and concentration (7-9).  
The exact underlying physiological 
mechanism of vasomotor symptoms is still 
illusive. Estrogen withdrawal (not low levels of 
estrogen) is thought to be the most probable expla- 
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nation for vasomotor symptoms as evidenced by 
its absence in gonadal dysgenesis and after some 
years of menopause, and the exaggerated and 
rapid onset of these symptoms after bilateral 
oophorectomy (10, 11). The withdrawal of 
estrogen leads to a reduction in the endorphin and 
catecholestrogen levels in the hypothalamus, 
which in turn enhances the release of 
norepinephrine and serotonin (12, 13). Elevated 
Norepinephrine and serotonin are thought to lower 
the set point in the thermoregulatory nucleus of 
the hypothalamus (14, 15).  
Taking into account the above proposed 
mechanism, selective serotonin reuptake inhibitors 
(SSRIs) and serotonin norepinephrine reuptake 
inhibitors (SNRIs), are under investigation for 
treatment of vasomotor symptoms (16–21). 
Furthermore, a meta-analysis of non-hormonal 
therapies (SSRIs or SNRIs, clonidine, gabapentin, 
red clover isoflavone extract and soy isoflavone 
extracts) has demonstrated their effectiveness in 
the treatment of hot flashes (22). However, the 
therapeutic effects of these non-hormonal 
compounds were not as good as estrogen and the 
primary studies included in that meta-analysis 
were found to have had methodological 
deficiencies (22).  
Of the non-hormonal compounds, 
venlafaxine is an antidepressant that acts by 
inhibiting the reuptake of serotonin and 
norepinephrine. Its effectiveness in the treatment 
of menopausal hot flashes appears comparable or 
superior to other non hormonal compounds like 
clonidine and gabapentine (23–26). Nevertheless, 
relative to clonidine, venlafaxine related adverse 
events were more prominent (23, 24).  
Desvenlafaxine, the major active metabolite of 
venlafaxine that is approved for the treatment of 
major depressive disorder, is also under 
investigation for treatment of menopausal 
vasomotor symptoms. Some clinical trials 
demonstrate its consistent effectiveness in 
reducing vasomotor symptoms (27–31); while 
another study doubted its effectiveness (32). The 
findings of the primary studies on desvenlafaxine 
effectiveness and safety in the treatment of 
menopausal vasomotor symptoms were 
inconclusive. A systematic review of four clinical 
trials pointed out that the desvenlafaxine treatment 
on hot flashes has inconsistent effectiveness 
results (33). Similarly, there were inconsistent 
results among the clinical trials in the rate of 
treatment discontinuation.  
A meta-analysis of desvenlafaxine efficacy 
and safety was done some before months by 
including six studies. However, the meta-analyses 
were performed with only desvenlafaxine doses of 
100mg and 150mg. Above all, although several 
statistically significant side effects were identified, 
a wrong conclusion was made by stating that 
desvenlafaxine appears safe (34).  
Thus, though it was speculated to be the first 
non-hormonal drug approved by the FDA for 
vasomotor symptoms treatment (35), its safety and 
effectiveness is not yet determined. With this 
background, the primary aim of this meta-analysis 
was to determine the effectiveness and safety of 
all assessed doses of desvenlavafaxine (50mg, 
100mg, 150mg and 200mg) in the treatment of 
menopausal vasomotor symptoms by including 




Search strategy: After coming to an agreement on 
search terms, electronic based literature search 
was conducted by two of the authors in the 
databases of HINARI, Medline and Cochrane 
library. Via HINARI, the websites of major 
publishers (Elsevier Science-Science Direct, 
Nature Publishing Group, Oxford University 
Press, PsycARTICLES, Science and Wiley-
Blackwell) were searched. Our search was further 
strengthened by Google scholar search engine and 
by searching relevant articles from the references’ 
list of retrieved articles. During searching, the 
following search terms were combined with the 
Boolean logic (and/or): “desvenlafaxine”, 
“serotonin-norepinephrine reuptake inhibitors” 
“hot flashes” “hot flushes”, “menopause” and 
“vasomotor symptoms”.  
Inclusion criteria and study selection: The pre-
defined inclusion criteria were: 1) double-blind 
randomized controlled studies that weighted the 
effectiveness and safety of desvenlafaxine against 
placebo in postmenopausal women who were 
seeking treatment for hot flashes and/or who 
experienced at least 7 moderate to severe hot 
flashes per day; and 2) studies that were published 
in English and have a duration of therapy not less 




than 12 weeks. The studies included in this work 
were published between 2005 and February 2013.  
Study selection was done by two of the authors in 
two phases. First, after the titles and abstracts of 
the retrieved literature were read, they were 
categorized as “eligible for further screening” and 
illegible for further screening”. Secondly, after 
screening the whole documents of literature 
grouped under “eligible for further screening”, 
they were grouped as “eligible for meta-analysis” 
and “illegible for meta-analysis”. When there was 
disagreement or difference in the grouping of 
specific articles, it was resolved by discussion and 
by reviewing the disputing article in detail. 
 
Data extraction: After developing a common data 
extraction template, the following data were 
abstracted from the selected studies using standard 
Excel spreadsheet: name of the first author, year 
of publication, study design, duration of therapy, 
dose, sample size, demographics and baseline 
clinical characteristics, mean change in the daily 
moderate to severe hot flashes from the baseline 
and standard deviation (SD) or standard error 
(SE), mean change in the daily severity score and 
SD/SE, mean change in the number of night time 
awakenings per night, the Greene climacteric scale 
(GCS) total score, proportion of women with ≥ 
50% reduction or ≥ 75% reduction in the moderate 
to severe hot flashes, number of women who 
discontinued the medication due to adverse events 
and number of women who experienced adverse 
events. 
 
Operational definitions: In all studies included, 
women who were taking any hormone therapy or 
other medications for the treatment of vasomotor 
symptoms during the clinical trials were excluded. 
Furthermore, the average daily hot flashes (HFs) 
severity was calculated as follows: [(number of 
mild HFs x 1) + (number of moderate HFs x 2) + 
(number of severe HFs x 3)]/total number of HFs 
on that day. The GCS total score (36) was 
determined only by assessing the vasomotor 
symptoms (hot flashes and night sweats). In this 
article, vasomotor symptoms and hot flashes are 
used interchangeably.  
Statistical analysis: Since there was moderate 
variability in the fixed effects model 
(heterogeneity testing showing 52% - 58% 
variability) of desvenlafaxine effectiveness in the 
treatment of vasomotor symptoms, the effect size 
for each study and the pooled effect were 
computed by the random effects model. Standard 
mean differences (SMDs) and 95% confidence 
intervals (95% CI) for the mean change in the 
number of daily moderate to severe hot flashes 
from the baselines, mean change in the daily 
severity score, mean change in the number of 
nighttime awakenings per night, and the GCS total 
score were computed using the inverse variance 
method. Mantel-Haenszel method was used to 
compute the odds ratios (OR) for hot flashes of 
greater than or equal to 50% and 75% reduction 
from baseline, and risk ratios (RR) for specific 
adverse events. 
The consistency of the treatment 
effectiveness across the included studies was 
assessed by the heterogeneity testing, chi-squared 
test (Cochrane Q test) and I
2
 statistics. An I
2
 value 
of ≥ 50% was considered as statistically 
significant. Subgroup analysis based on doses of 
desvenlafaxine and linear meta-regression analysis 
for several covariates or moderators (women’s 
age, baseline BMI, baseline severity of hot flashes, 
duration from menopause and the proportion of 
women with natural menopause) were conducted 
to examine the sources of heterogeneity. Similarly, 
sensitivity analysis (leaving one study out a time 
analysis) was done to assess the stability of the 
pooled values to outliers and the change in 
heterogeneity. Risk of bias of individual studies 
was evaluated with the Cochrane risk of bias tool. 
However, since the studies included in this meta-
analysis were fewer than ten, the tests for funnel 
plot asymmetry were not done as recommended 
(37). All the statistical analyses were conducted 
using OpenMeta (analyst) software and 




As presented in Figure 1 (PRISMA flow chart), 
through database search, 1,010 articles were 
identified. Based on proximity of the titles to the 
objective of this meta-analysis, 70 articles were 
retrieved. After reviewing the abstracts of the 
retrieved articles, 15 articles were eligible for full 
document screening. Finally only 7 articles (27 – 
32, 38) met the pre-defined inclusion criteria. Four 
of the studies (27, 28, 32, 38) compared the 





effectiveness and safety of 100mg/day of 
desvenlafaxine against placebo; three of the 
studies (30, 31, 38) tested two doses of 
desvenlafaxine (100 mg /day and 150 mg/day) 
against placebo; and two studies (29, 38) tested 
four doses of desvenlafaxine (50 mg/day, 100 
mg/day, 150 mg/day and 200 mg/day) against 
placebo. The risk of bias assessment did not show 


























Figure 1: Flow diagram showing studies selection 
 
Overall, in these studies, 2020 women received 
desvenlafaxine, and 1665 women received 
placebo. Among desvenlafaxine treated, with 
moderate inconsistency (I
2
 = 52%), the meta-
analysis showed a statistically significant 
reduction in the number of daily moderate to 
severe hot flashes from the baseline (over all SMD 
= -0.3; 95% CI, -0.41 to -0.22) (Figure 2). Except 
in one study (32), desvenlafaxine 100mg/day has 
significantly reduced the recurrence of moderate 
to severe hot flashes. In other two studies (29, 38), 
although the actual value of the SMD inclines to 
the left, neither too low (50 mg) nor too high (200 
mg) dose of desvenlafaxine showed statistically 
significant reduction in the number of daily 
moderate to severe hot flashes.  
In another analysis, a large number of women 
in the desvenlafaxine treated group have achieved 
a reduction in the number of daily moderate to 
severe hot flashes by ≥ 50% (overall OR = 2.5; 
95% CI, 1.84 to 3.30) and ≥ 75% (overall OR = 
2.1; 95% CI, 1.65 to 2.53) from the baseline  (28, 
30-32).  
Meta-regression showed that desvenlafaxine 
treatment outcome was not dependent on women’s 
age, baseline body mass index (BMI), duration 
after menopause, baseline severity and frequency 
of hot flashes. Interestingly, desventlafaxine 
treatment seems more effective in the natural 
menopause than in the bilateral ophorectomy 
group (regression coefficient =−0.01; 95% CI,-
0.263 to 0.002; P=0.053).  
On the other hand, the subgroup analysis 
based on desvenlafaxine dose (50 mg/day, 100 
mg/day, 150 mg/day and 200 mg/day) did not 
demonstrate a significant variation in the mean 
change of daily moderate to severe hot flashes. 
The sensitivity analysis, however, verified the 
stability of the overall SMD (with the withdrawal 
of any of the studies from the analysis, the overall 
SMD swings between -0.30 and -0.38). However, 
when Bouchard et al study (32) was withdrawn 
from the analysis; there was a significant 
reduction in the heterogeneity testing (I
2 
drops 
from 52% to 37%).  
 
1,010 literature were identified through 
databases searching 
 
940 publications were excluded 
after reviewing the titles 
55 publications were excluded 
after reviewing the abstracts 
 
70 publications were retrieved  
8 articles were excluded after 
full document review   
15 articles were accepted for 
detailed review  
7 articles were included in this 
meta-analysis  





Figure 2: Standardized mean difference of the change in the number of daily moderate to severe hot flashe from the 
baseline 
 
As shown in figure 3, the meta-analysis of the 
daily hot flashes severity score has demonstrated a 
significant reduction in the severity of hot flashes 
in the desvenlafaxine treated groups (overall SMD 
= -0.3; 95% CI, -0.38 to -0.17). However, 
heterogeneity testing still showed the existence of 
a moderate variability among the included studies 
(I
2
 = 58%). In the subgroup analysis based on the 
doses of desvenlafaxine, the significant 
heterogeneity among the studies was not also 




Figure 3: Standardized mean difference of the change in the daily hot flashes severity score (The Greene climacteric 
scale) 
 
The meta-analysis of awakenings per night 
because of hot flashes and the change in the GCS, 
total score have brought additional evidence to 
support desvenlafaxine effectiveness in the 
treatment of hot flashes. In other words, the 
number of awakenings per night because of hot 
flashes (overall SMD = -0.3; 95% CI, -0.38 to -
0.20) (Figure 4) and GCS total score (overall 
SMD = -0.3; 95% CI, -0.36 to -0.20) were 
significantly decreased from baseline in 
desvenlafaxine treated groups.  
 






Figure 4: Standardized mean difference of the change in the number of nighttime awakenings due to hot flashes 
 
As shown in figure 5, the overall rate of 
desvenlafaxine discontinuation because of adverse 
events was significantly higher than placebo 
treated women (overall OR = 2.4; 95% CI, 1.87 to 
3.15). The rate of discontinuation due to 
desvenlafaxine adverse events was higher in those 
treated with 150mg and 200 mg with the exception 
of one study (31).  
 
 
Figure  5: Mantel-Haenszel odds ratio of desvenlafaxine treatment discontinuation due to adverse events  
 
Table 1 summarizes 12 meta-analyses. Hot flashes 
treated with desvenlafaxine was found to have a 
highly statistically significant association with 
several adverse events like asthenia (OR = 2.3), 
hypertension (OR = 2.2), anorexia (OR = 3.6), 
constipation (OR = 2.5), diarrhea (OR = 1.6), dry 
mouth (OR = 5.9), nausea (OR = 4.3), dizziness 
(OR = 2.4), insomnia (OR = 1.9), somnolence (OR 
= 4.8) and mydriasis (OR = 7.5) (Table1). As 
evidenced by their high risk ratios, the majorities 
of adverse events were encountered among 
women who were treated with high doses of 
desvenlafaxine (150mg and 200mg).    














Number of participants 
(Desvenlafaxine/placebo) 
Any adverse events 1.15 [1.08 - 1.22]** 56% 1271/952 
Asthenia 2.25 [1.67 - 3.03]*** 12% 1432/1122 
Hypertension 2.16 [1.30 - 3.61]** 0% 1274/970 
Anorexia 3.56 [2.09 - 6.06]*** 0% 1274/970 
Constipation 2.51 [1.79 - 3.53]*** 49% 2698/2364 
Diarrhea 1.57 [1.10 - 2.23]* 10% 1474/1160 
Dry mouth 5.87 [4.34 - 7.95]*** 0% 2698/2364 
Nausea 4.31 [3.40 - 5.46]*** 40% 2698/2364 
Dizziness 2.39 [1.97 - 2.91]*** 0% 2498/2174 
Insomnia 1.94 [1.54 - 2.44]*** 0% 1432/1122 
Somnolence 4.81 [3.41 - 6.79]*** 0% 2698/2364 
Mydriasis 7.52 [2.66 - 21.24]** 0% 1274/970 




In support of previous meta-analyses done on 
other non-hormonal compounds (22, 39), this 
meta-analysis has demonstrated a significant 
reduction of recurrence and severity of 
menopausal hot flashes in women who were 
treated with desvenlafaxine. Furthermore, a 
significant number of women who were treated 
with desvenlafaxine achieved a greater than or 
equal to 75% reduction in the number of daily 
moderate to severe hot flashes. Among women 
who were treated with desvenlafaxine, the number 
of nighttime awakenings per night due to hot 
flashes also dropped significantly. However, a 
significant number of women who were treated 
with desvenlafaxine experienced more adverse 
events and discontinuation of the drug than 
placebo treated women.  
The high statistically significant association 
of desvenlafaxine with all selected adverse events 
(Risk ratio as high as 7.5), which was 
complemented by more than 2.4-fold increased 
odds of treatment discontinuation due to adverse 
events, makes the safety and tolerability of this 
drug for the treatment of perimenopausal 
vasomotor symptoms questionable. However, it 
should be noted that the majority of the women 
who discontinued the desvenlafaxine treatment 
were put on relatively high dose, which probably 
indicates the dose related adverse events as stated 
in Speroff et al clinical trial (29). Furthermore, the 
finding of higher risk ratio of adverse events 
among women treated with high dose 
desvenlafaxine is also another evidence to 
question the safety margin of desvenlafaxine. 
Dose titration and tapering may be options to 
alleviate the observed adverse events and 
treatment discontinuation as reported in one of the 
clinical trials (31) and recommended by reviewers 
(33). Literature reviews have also shown that 
adverse events are the major problems of several 
other non-hormonal agents used for the treatment 
of hot flashes (40, 41).   
However, in a study focusing only on adverse 
events, it was reported that menopausal vasomotor 
symptoms treated with desvenlafaxine 100mg/day 
compared with placebo did not show an increased 
risk of cardiovascular (including hypertension), 
cerebrovascular, or hepatic events (40). This is 
probably because of the fact that the studies 
included in this meta-analysis were not primarily 
designed to address the side effects of 
desvenlafaxine, which could be taken as a 
limitation to draw a conclusion. As recommended 
in a literature (42), since the sample sizes of the 
individual studies included in a meta-analysis did 
not provide adequate power to test rare adverse 
events, a separate research design has to be 
developed primarily intended to assess the adverse 
events. This is also one of the recommendations of 
this meta-analysis before declaring the safety and 
tolerability of desvenlafaxine. 





Until proved otherwise, however, desvenlafaxine 
100mg/day seems effective and relatively safe in 
the treatment of vasomotor symptoms. The 
desvenlafaxine 50mg/day dose was not effective 
in all assessed outcome indicators (change in 
nighttime awakenings, frequency and severity of 
hot flashes), but it was not strongly associated 
with treatment discontinuation and adverse events 
probably because it was well tolerated. The 
desvenlafaxine 150mg/day and 200mg/day doses 
were not also consistently effective, but were 
strongly associated with treatment discontinuation 
and adverse events in the majority of the clinical 
trials. Furthermore, there was no significant 
difference in the proportion of hot flashes among 
women treated with 100 mg, 150 mg and 200mg; 
the symptom reduction was in the range of 60%-
65% (29-31). Therefore, the authors would like to 
recommend clinical trials focusing only on 
adverse events of desvenlafaxine with a dose of 
100mg/day.  
Meta-regression has shown that 
desvenlafaxine treatment seems more effective in 
women with the natural than in the surgical 
menopause. However, this finding should be 
interpreted very cautiously. Firstly, the number of 
women with surgical menopause was less than 
one-third of the women with the natural 
menopause, which may not be representative of 
the general population. Secondly, the course of 
estrogen withdrawal (attributed for vasomotor 
symptoms) in the natural menopause is a slow 
process, while in the surgical case, it is an abrupt 
onset. Surgical menopause is known to have fast 
onset and severe vasomotor symptoms (33, 43, 44) 
that may not respond to desvenlafaxine treatment. 
Thirdly, although the meta-regression did not 
demonstrate significant variation, it is known that 
the longer the duration of postmenopause, the 
lesser the severity of vasomotor symptoms, which 
is likely to happen more in the natural than in the 
surgical menopause.   
In general, so far, the most effective 
treatment that is approved by the Food and Drug 
Administration of America (FDA) for vasomotor 
symptoms is hormone replacement therapy. 
Nevertheless, there are several absolute 
(unexplained vaginal bleeding, thromboembolic 
disease, breast cancer, severe liver disease, 
coronary artery disease, type I endometrial cancer) 
and relative (migraine headache, ovarian cancer, 
leiomyoma, and gall bladder disease) 
contraindications for hormonal therapy (45, 46). 
Specific to breast cancer, since antiestrogenic 
medications and ophorectomy are part of the 
treatment modalities, vasomotor symptoms are 
more common and severe (43, 44). As a result, 
desvenlafaxine can have several indications to 
treat vasomotor symptoms provided that the safety 
margin and patients’ compliance are re-evaluated. 
This study has several limitations. Among the 
studies included in it, the heterogeneity testing 
showed moderate variability. Although the 
subgroup analysis and meta-regression did not 
support our assumptions, several factors are 
attributed to the observed heterogeneity: the 
desvenlafaxine dose variation, baseline differences 
in severity and frequency of hot flashes, women’s 
age and BMI, ethnicity, duration since menopause, 
and type of menopause (surgical or natural). 
Furthermore, previous hormonal therapies and 
adjuvant traditional therapies during the clinical 
trials were not reported in the selected studies. The 
duration of therapy in the clinical trials was also 
limited to 12 weeks. What is more, we are not sure 
that we have missed articles written in non-
English languages.  
In conclusion, this meta-analysis has shown 
that desvenlafaxine was associated with a 
statistically significant reduction in the number 
and severity of daily moderate to severe hot 
flashes from the baseline. Similarly, the number of 
nighttime awakenings because of hot flashes was 
significantly decreased. Desventlafaxine treatment 
seems more effective in women with the natural 
than with the surgical menopause. However, the 
rate of desvenlafaxine discontinuation because of 
adverse events was a significantly higher than 
placebo treated women and the risk ratios of 
adverse events like asthenia, hypertension, 
anorexia, constipation, diarrhea, dry mouth, 
nausea, dizziness, insomnia, somnolence and 
mydriasis were very high. In the treatment of hot 
flashes, further clinical trials on desvenlafaxine 
related adverse events are highly warranted before 
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